Target- |
MechanismPhotosensitizers |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date29 Sep 2016 |
奥贝胆酸片治疗原发性胆汁性胆管炎的有效性和安全性的多中心、随机、双盲双模拟、安慰剂对照桥接临床试验
[Translation] A multicenter, randomized, double-blind, double-dummy, placebo-controlled bridging clinical trial to evaluate the efficacy and safety of obeticholic acid tablets in the treatment of primary biliary cholangitis
评价奥贝胆酸片对比安慰剂治疗中国原发性胆汁性胆管炎患者的有效性和安全性。
[Translation] To evaluate the efficacy and safety of obeticholic acid tablets compared with placebo in the treatment of Chinese patients with primary biliary cholangitis.
[Translation] A post-marketing safety evaluation study of T0004 in the treatment of port-wine stains
在临床应用真实使用条件下观察T0004的少见不良反应,进一步评价药物的安全性。
[Translation] Observe the rare adverse reactions of T0004 under real clinical usage conditions and further evaluate the safety of the drug.
T0004光动力学治疗7-14岁儿童鲜红斑痣的探索性研究
[Translation] T0004 Exploratory study on photodynamic therapy for port wine stains in children aged 7-14 years
探索本品光动力学治疗7-14岁儿童鲜红斑痣的合理光照剂量;考察其在7-14岁儿童体内的药物动力学行为及药物动力学参数;观察其治疗儿童鲜红斑痣的安全性和有效性。
[Translation] To explore the reasonable light dose of this product for photodynamic therapy of port wine stains in children aged 7-14 years; to investigate its pharmacokinetic behavior and pharmacokinetic parameters in children aged 7-14 years; and to observe its safety and efficacy in treating port wine stains in children.
100 Clinical Results associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
100 Deals associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.